The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Main results from the ANDROMEDA study
Raymond Comenzo
• 1 Jun 2020
Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, discusses the main findings from the ANDROMEDA study (NCT03201965), comparing efficacy and safety of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).
